Compare Inovio Pharmaceuticals Inc (INO) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs VF Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $1.14 (market cap $112.19M), while VF Corp trades at $15 (market cap $5.65B). The key difference: VF Corp is far larger — about 50.4× Inovio Pharmaceuticals Inc's market cap, and VF Corp pays a 2.5% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and VF Corp for 64 Days on average.
| INO | VFC | |
|---|---|---|
Market Cap | $112.19M | $5.65B |
Volume | 3,201,278 | 6,542,273 |
Sector | Health | Consumer Cyclical |
52-Week High | $2.65 | $21.55 |
52-Week Low | $0.66 | $12.62 |
Typical Hold Time | 43 Days | 64 Days |
Enterprise Value | $83.51M | $9.94B |
Dividend Yield | — | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.155, up 2.21% today, while showing bearish technical signals with negative cash flow and substantial losses. The company's financials reveal minimal revenue of $65,340 against an $84.95 million net loss in 2025, with profitability metrics deeply negative. However, analyst sentiment is optimistic with a 58.83% buy rating and $2.75 consensus price target, driven by the upcoming FDA decision on INO-3107 for recurrent respiratory papillomatosis by October 30, 2026.
INO presents high-risk speculation with potential for significant upside if FDA approval is secured, but carries substantial fundamental weaknesses including persistent cash burn and negative margins. Investors should weigh the binary outcome of the regulatory decision against the company's challenging financial position and technical bearishness.
VFC trades at $14.38, down 0.48% on the day, with a mixed technical picture showing a bullish moving average signal but neutral oscillators. The stock is near its 52-week low, reflecting ongoing challenges. Recent earnings have been volatile, with two misses in the last three quarters, and the company reported a net loss of $189.72 million for 2025. Revenue has declined from $11.8 billion in 2022 to $9.5 billion in 2025, though 2026 projects a return to profitability.
The outlook for VFC hinges on executing its turnaround amid weak Vans performance. The stock's discounted valuation (P/E of 20.84, P/S of 0.6) offers potential upside if brand recovery gains traction, but high execution risk and competitive pressures pose significant threats. Analyst consensus is mixed with a Hold rating, and the stock faces near-term resistance at $15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
